News Releases

November 7, 2012

RepliCel Completes First Pre-Filing Review with German Competent Authority on its RCH-01 Autologous Hair Cell Manufacturing Pro
Phase II Dose Ranging Trial on its Hair Cell Replication Technology Expected to Commence Mid-2013 VANCOUVER, BC – November 7, 2012 – RepliCel Life... Read full article

September 27, 2012

RepliCel’s Common Shares Listed on CNSX
VANCOUVER, BC – October 1, 2012  – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB:REPCF) today announces that its common shares have been... Read full article

September 26, 2012

RepliCel’s Chief Medical Officer to Present at 21st European Academy of Dermatology & Venereology Congress
VANCOUVER, BC – September, 26, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB:REPCF) today announces that Dr. Rolf Hoffmann, RepliCel’s Chief Medical Officer, will... Read full article

September 10, 2012

RepliCel to Present at Rodman and Renshaw Global Investment Conference
VANCOUVER, BC – September 10, 2012 – RepliCel Life Sciences Inc.’s (the “Company” or “RepliCel”) (OTCBB:REPCF) today announces that David Hall, CEO and President, will be presenting... Read full article

June 26, 2012

RepliCels Chief Scientific Officer Updates European Hair Research Society on RepliCels TS001-2009 First-in-man Clinical Trial
VANCOUVER, BC – June 26, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB:REPCF) Chief Scientific Officer, Dr. Kevin McElwee, presented results from the Company’s... Read full article

May 17, 2012

Further Analysis Reveals Double Digit Hair Growth in RepliCels First-in-man Clinical Trial
Company Takes Next Steps for Phase IIb Dosing Trial VANCOUVER, BC – May 17, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)... Read full article

May 2, 2012

RepliCel Releases Positive Results from the Interim Analysis of Data from its First-in-man TS001-2009 Clinical Trial
VANCOUVER, BC – May 2, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF)  is pleased to report positive results from... Read full article